Literature DB >> 12218388

Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.

Mario Clerici1, Elena Seminari, Franco Maggiolo, Angelo Pan, Marco Migliorino, Daria Trabattoni, Francesco Castelli, Fredy Suter, Maria Luisa Fusi, Lorenzo Minoli, Giampiero Carosi, Renato Maserati.   

Abstract

BACKGROUND: Control of HIV replication can be observed in highly active antiretroviral therapy (HAART)-treated and, occasionally, in HAART-naive patients. The immunological correlates of these situations were examined in a longitudinal study.
DESIGN: A prospective study. Immunovirological analyses in 16 chronically HIV-infected, HAART-naive patients (time 0) who started HAART. Fifteen patients (short-term HAART) were re-evaluated after 24 months (time 1). Results were compared with those of 30 patients who received HAART for more than 12 months before the study period (long-term HAART) and were analysed at the same timepoints. Fifteen patients who were antiviral therapy naive (naive) at both timepoints were also studied.
RESULTS: Over a 24-month period CD4 and CD8 cell counts and viraemia remained unchanged in naive and long-term HAART patients; CD4 cell counts increased and viraemia diminished in short-term HAART individuals. Antigen-stimulated proliferation was unmodified in naive and short-term HAART patients, but improved in long-term HAART individuals. Gp160-stimulated IL-2 and IFN-gamma production was augmented in long-term HAART patients and marginally modified in other patients. IL-7 production was unmodified in naive individuals, augmented in short-term HAART patients, and diminished in long-term HAART patients. Chemokine production was similar in all patients. Naive patients showed the highest CD8 cell counts at both timepoints.
CONCLUSION: HAART has a major impact on the outcome of HIV infection, even if functional immune modulation in HAART-treated patients is evident only after long periods of therapy. Low but detectable HIV replication in HAART-naive patients with preserved immune functions might not be associated with CD4 cell reduction, functional immune defects, or changes in viraemia. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218388     DOI: 10.1097/00002030-200209060-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy.

Authors:  Daria Trabattoni; Monica Schenal; Miriam Cesari; Eleonora Castelletti; Michela Pacei; Billi Goldberg; Andrea Gori; Mario Clerici
Journal:  Med Microbiol Immunol       Date:  2006-01-26       Impact factor: 3.402

2.  Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS.

Authors:  Mark L Ettenhofer; Jessica Foley; Steven A Castellon; Charles H Hinkin
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

3.  To tell or not to tell: why people with HIV share or don't share with their physicians whether they are taking their medications as prescribed.

Authors:  H Kremer; G Ironson
Journal:  AIDS Care       Date:  2006-07

Review 4.  Functional consequences of HIV-associated neuropsychological impairment.

Authors:  Ashley A Gorman; Jessica M Foley; Mark L Ettenhofer; Charles H Hinkin; Wilfred G van Gorp
Journal:  Neuropsychol Rev       Date:  2009-05-27       Impact factor: 7.444

5.  Aging, neurocognition, and medication adherence in HIV infection.

Authors:  Mark L Ettenhofer; Charles H Hinkin; Steven A Castellon; Ramani Durvasula; Jodi Ullman; Mona Lam; Hector Myers; Matthew J Wright; Jessica Foley
Journal:  Am J Geriatr Psychiatry       Date:  2009-04       Impact factor: 4.105

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.